Inventera: FDA clears Phase 1 trial of INV003, MRCP-specific contrast agent

FDA approves IND for Phase 1 trial of contrast agent INV003

Key figures: FDA clears Phase 1 IND

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

• 09.21 ★★★★ Receives final Phase 3 clinical trial report for contrast agent INV-002
• 09.17 ★★★ Applies for FDA Phase 1 IND for contrast agent INV-003